Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Latest News

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

View Press Release View All

Rigel Pharmaceuticals Provides Business Update

Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022
Earnings Release
PDF HTML
Audio
Earnings Webcast
Earnings Presentation
PDF
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Report Links

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
611 Gateway Blvd
Suite 900
South San Francisco, CA 94080

Investor Relations

Rigel Pharmaceuticals, Inc.
ir@rigel.com

Transfer Agent

EQ Shareowner Services
T: 800-401-1957